Cytochrome P450 Mediated-drug Metabolism is Reduced in Children with Sepsis-induced Multiple Organ Failure

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2003 Apr 17

PMID 12698250

Citations 41

Authors

Joseph A Carcillo

Lesley Doughty

Danny Kofos

Reginald F Frye

Sandra S Kaplan

Howell Sasser

Gilbert J Burckart

Affiliations

Soon will be listed here.

Abstract

Objective: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans. Cytokines (e.g., interleukin-6) and nitric oxide reduce CYP 450 activity in vitro and in vivo. Because interleukin-6 and nitric oxide production increases in children with sepsis-induced multiple organ failure, we hypothesized impaired CYP 450 mediated drug metabolism in this population.

Methods: Fifty-one consecutive children with sepsis and six critically ill children without sepsis were enrolled and given 18 mg/kg antipyrine per NG. Plasma antipyrine elimination rate, elimination half-life, and apparent oral clearance were measured and calculated. Plasma interleukin-6 and nitrite plus nitrate levels were measured and organs failing scored on days 1-3 of sepsis.

Results: Children with sepsis had a twofold reduction in antipyrine clearance. Children with persistent failure of three or more organs had a fourfold reduction in antipyrine clearance. Antipyrine clearance was inversely correlated to circulating interleukin-6 and nitrite plus nitrate levels and to number of organ failures.

Conclusions: Interpretation CYP 450 mediated drug metabolism is decreased in children with sepsis, related in part to the degree of inflammation and organ failure. For drugs metabolized by CYP 450 enzymes there is an urgent need to reevaluate the use of standard drug dosage schedules in the sepsis population

Citing Articles

Immunomodulation by Hemoadsorption-Changes in Hepatic Biotransformation Capacity in Sepsis and Septic Shock: A Prospective Study.

Praxenthaler J, Schwier E, Altmann S, Kirchner C, Bialas J, Henzler D Biomedicines. 2022; 10(10).

PMID: 36289602 PMC: 9598581. DOI: 10.3390/biomedicines10102340.

The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease....

Gatti M, Pea F Clin Pharmacokinet. 2022; 61(11):1519-1544.

PMID: 36059001 PMC: 9441320. DOI: 10.1007/s40262-022-01173-8.

Dexmedetomidine in Children on Extracorporeal Membrane Oxygenation: Pharmacokinetic Data Exploration Using Previously Published Models.

Thibault C, Zuppa A Front Pediatr. 2022; 10:924829.

PMID: 35832579 PMC: 9271626. DOI: 10.3389/fped.2022.924829.

Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics.

Humphreys S, Davis J, Iqbal S, Kamel A, Kulmatycki K, Lao Y Nucleic Acids Res. 2022; 50(11):6020-6037.

PMID: 35687098 PMC: 9226521. DOI: 10.1093/nar/gkac456.

Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients.

Grimsrud K, Davis R, Tepper C, Palmieri T J Burn Care Res. 2022; 43(5):987-996.

PMID: 35639664 PMC: 9435482. DOI: 10.1093/jbcr/irac062.

References

Danhof M, Breimer D . Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol. 1979; 8(6):529-37. PMC: 1429894. DOI: 10.1111/j.1365-2125.1979.tb01040.x. View

Renton K . Hepatic drug metabolism and immunostimulation. Toxicology. 2000; 142(3):173-8. DOI: 10.1016/s0300-483x(99)00142-0. View

Proulx F, Fayon M, Farrell C, Lacroix J, Gauthier M . Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996; 109(4):1033-7. DOI: 10.1378/chest.109.4.1033. View

Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M . Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996; 59(6):613-23. DOI: 10.1016/S0009-9236(96)90001-6. View

St Peter J, Awni W . Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet. 1991; 20(1):50-65. DOI: 10.2165/00003088-199120010-00004. View

Chang K, Bell T, Lauer B, Chai H . Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978; 1(8074):1132-3. PMC: 7135825. DOI: 10.1016/s0140-6736(78)90305-7. View

Muller C, Scierka A, STILLER R, Kim Y, Cook D, Lancaster Jr J . Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology. 1996; 84(6):1435-42. DOI: 10.1097/00000542-199606000-00020. View

Doughty L, Kaplan S, Carcillo J . Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med. 1996; 24(7):1137-43. DOI: 10.1097/00003246-199607000-00012. View

Morgan E . Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1998; 29(4):1129-88. DOI: 10.3109/03602539709002246. View

10.

Wilkinson J, Pollack M, Glass N, Kanter R, Katz R, Steinhart C . Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987; 111(3):324-8. DOI: 10.1016/s0022-3476(87)80448-1. View

11.

Pape D, Lehmann U, Oellerich M, Regel G . [Multiple organ failure after severe trauma: predictable by the MEGX liver function test?]. Langenbecks Arch Chir Suppl Kongressbd. 1996; 113:338-9. View

12.

Wong H, Carcillo J, Burckart G, Kaplan S . Nitric oxide production in critically ill patients. Arch Dis Child. 1996; 74(6):482-9. PMC: 1511570. DOI: 10.1136/adc.74.6.482. View

13.

Homeida M, Roberts C, Halliwell M, Read A, Branch R . Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. Gut. 1979; 20(7):596-601. PMC: 1412524. DOI: 10.1136/gut.20.7.596. View

14.

Shedlofsky S, Israel B, Tosheva R, Blouin R . Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol. 1997; 43(6):627-32. PMC: 2042794. DOI: 10.1046/j.1365-2125.1997.00603.x. View

15.

ROBERTS E, Lin H, Crowley J, Vuletich J, Osawa Y, Hollenberg P . Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1. Chem Res Toxicol. 1998; 11(9):1067-74. DOI: 10.1021/tx980099b. View

16.

Loyer P, Fautrel A, GAUTIER J, Corcos L, Turlin B, Beaune P . Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993; 44(4):707-15. View

17.

Kraemer M, Furukawa C, Koup J, Shapiro G, Pierson W, BIERMAN C . Altered theophylline clearance during an influenza B outbreak. Pediatrics. 1982; 69(4):476-80. View

18.

Doughty L, Carcillo J, Kaplan S, Janosky J . Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med. 1998; 26(1):157-62. DOI: 10.1097/00003246-199801000-00032. View

19.

Shedlofsky S, Israel B, McClain C, Hill D, Blouin R . Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest. 1994; 94(6):2209-14. PMC: 330046. DOI: 10.1172/JCI117582. View

20.

Eichelbaum M, Ochs H, Roberts G, Somogyi A . Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Arzneimittelforschung. 1982; 32(5):575-8. View